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Prediction of Residual Retroperitoneal Mass Histology
After Chemotherapy for Metastatic Nonseminomatous
Germ Cell Tumor: Multivariate Analysis of Individual
Patient Data From Six Study Groups
By E.W. Steyerberg, H.J. Keizer, S.D. Foss6, D.Th. Sleijfer, G.C. Toner, H. Schraffordt Koops, P.F.A. Mulders,
J.E. Messemer, K. Ney, J.P. Donohue, D. Bajorin, G. Stoter, G.J. Bosl, and J.D.F. Habbema
Purpose: To develop a statistical model that predicts
the histology (necrosis, mature teratoma, or cancer) after
chemotherapy for metastatic nonseminomatous germ
cell tumor (NSGCT).
Patients and Methods: An international data set was
collected comprising individual patient data from six
study groups. Logistic regression analysis was used to
estimate the probability of necrosis and the ratio of can-
cer and mature teratoma.
Results: Of 556 patients, 250 (45%) had necrosis at
resection, 236 (42%) had mature teratoma, and 70 (13%)
had cancer. Predictors of necrosis were the absence of
teratoma elements in the primary tumor, prechemother-
apy normal alfa-fetoprotein (AFP), normal human chori-
onic gonadotropin (HCG), and elevated lactate dehydro-
genase (LDH) levels, a small prechemotherapy or
postchemotherapy mass, and a large shrinkage of the
SURGICAL RESECTION is a generally accepted
treatment for residual retroperitoneal masses after
chemotherapy for metastatic testicular nonseminomatous
germ cell tumor (NSGCT).'"2 Resection may reveal necro-
sis/fibrosis, mature teratoma, or cancer. Because these
three histologies are not considered to have a similar
necessity of resection, attempts have been made to predict
the postchemotherapy histology.3" For patients with a
very high likelihood of necrosis, the risk of leaving ma-
ture teratoma or cancer unresected might not be balanced
by the disadvantages of resection (morbidity, mortality,
financial costs).
The decision to perform surgical resection is especially
difficult in patients with small residual masses. In some
centers, resection is performed if the residual mass ex-
ceeds an arbitrarily chosen size (eg, 20 mm6 or 10 mm 7"8),
with the argument that the probability of cancer or mature
teratoma is very low in smaller masses. When no patho-
logic mass can be detected on the postchemotherapy com-
puted tomography (CT) scan, some surgeons still advo-
cate resection in the following situations: if a teratomatous
component is present in the primary tumors; if a preche-
motherapy abdominal lymph node metastasis is greater
than 30 mm3; or if resection is performed as a principle
in all patients.'" The fraction of resected patients varies
from approximately 25% (masses > 20 mm6 ) to 86% in
accordance with the selection criteria."1 The extent of
surgery is debatable; some surgeons excise only visible
mass during chemotherapy. Multivariate combination of
predictors yielded reliable models (goodness-of-fit tests,
P > .20), which discriminated necrosis well from other
histologies (area under the receiver operating character-
istic (ROC) curve, .84), but which discriminated cancer
only reasonably from mature teratoma (area, .66). Inter-
nal and external validation confirmed these findings.
Conclusion: The validated models estimate with high
accuracy the histology at resection, especially necrosis,
based on well-known and readily available predictors.
The predicted probabilities may help to choose between
immediate resection of a residual mass or follow-up, tak-
ing into account the expected benefits and risks of resec-
tion, feasibility of frequent follow-up, the financial costs,
and the patient's individual preferences.
J Clin Oncol 13:1177-1187. O 1995 by American So-
ciety of Clinical Oncology.
abnormal masses,6 whereas others perform a more exten-
sive retroperitoneal lymph node dissection."
In addition to the size of the residual mass, other char-
acteristics may be considered in the decision to resect a
residual mass. Previously recognized predictors of necro-
sis include the absence of teratoma elements in the pri-
mary tumor, prechemotherapy tumor marker levels
(alfa-fetoprotein [AFP], human chorionic gonadotropin,
[HCG], and lactate dehydrogenase [LDH]), prechemo-
therapy and postchemotherapy mass size, and shrinkage
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Table 1. Characteristics of the Six Participating Study Groups
Study Principal
No. Investigator References Study Group N
1 Toner 3 MSKCC, New York, NY 122
2 Foss6 5,13,14 NRH, Oslo, Norway 127
3 Sleijfer 9,15,20,21 UH, Groningen, the 137
Netherlands
4 Mulders 8 UH, Nijmegen, the 34
Netherlands
5 Donohue 4 IU, Indianapolis, IN 51
6 Steyerberg 7 UH, Leiden; RCI, Rotterdam; 85
FU, Amsterdam, the
Netherlands
Abbreviations: MSKCC, Memorial Sloan-Kettering Cancer Center; NRH,
Norwegian Radium Hospital; UH, University Hospital; IU, Indiana Univer-
sity; RCI, Rotterdam Cancer Institute; FU, Free University.
during chemotherapy.3-58,9,12-19 The same predictors may
help to distinguish cancer from teratoma. In this analysis,
our aim is to estimate the probabilities of necrosis, mature
teratoma, and cancer in residual retroperitoneal masses
based on these well-known and readily available pre-
dictors. To obtain a sufficiently large number of patients
for statistical analyses, we collected an international data
set comprising data from six study groups.
PATIENTS AND METHODS
Inclusion Criteria
The international data set consisted of patients with metastatic
nonseminomatous testicular cancer, including patients with pure
seminoma and elevated prechemotherapy tumor marker levels, who
underwent resection of retroperitoneal residual masses after cis-
platin-based induction chemotherapy. Patients with elevated levels of
tumor markers AFP or HCG at the time of surgery, with extragonadal
tumors, with pure seminoma (normal prechemotherapy AFP and
HCG), and those who underwent resection after relapse of tumor
after initial chemotherapy were excluded.
Study Descriptions
Individual patient data were retrieved according to a data form
that included basic patient identification, year and type of treatment,
histology, and information on the following predictors: presence of
teratoma elements in the primary tumor, prechemotherapy tumor
marker levels (AFP, HCG, LDH), and prechemotherapy and postche-
motherapy mass size. Consistency of the data was checked with the
participants (agreement with published figures and completion of
missing values as far as possible). The studies are numbered I to 6
(Table 1) and are briefly described here; details of treatment and
resection policy can be found in the original publications. Study no.
1V included 122 patients, all of whom fulfilled the inclusion criteria.
Study no. 25,13,14 included 149 patients, 22 of whom were excluded
(11 with extragonadal tumors, 10 with elevated postchemotherapy
marker levels (AFP/HCG), and one with both characteristics). Study
no. 39,15,20,21 included 137 patients. Study no. 4' included 49 patients,
15 of whom were excluded (11 with pure seminomas and four with
elevated marker levels before surgery). Study no. 54 included 80
cases with initial stage B3 disease (palpable prechemotherapy mass
> 10 cm). Seventeen patients who underwent salvage chemotherapy
for recurrent disease, five patients with pure seminoma, and one
patient with an elevated postchemotherapy AFP level were excluded.
Of the 51 remaining patients, 50 did not have a prechemotherapy
LDH value recorded. Study no. 6' included 85 Dutch patients, all
of whom fulfilled the inclusion criteria. The European centers partici-
pated in consecutive trials of the European Organization for Research
and Treatment of Cancer (EORTC) or Medical Research Council
(MRC). In total, 556 patients were included in the analysis.
Definitions of Predictors and Histology
The primary tumor histology was defined as teratoma-positive
or teratoma-negative, 34 according to whether teratomatous elements
were present. The AFP, HCG, and LDH tumor marker levels before
chemotherapy were classified as elevated or normal by comparison
with the normal values of each center. Higher cutoff points and
transformations (square root, log) were evaluated for the absolute
values of AFP and HCG and for standardized values of LDH (LDHst;
LDH value divided by normal value per study).22 Prechemotherapy
and postchemotherapy mass size was measured in transversal direc-
tion on CT scan. Shrinkage was calculated as the percentage reduc-
tion in size: 100. (presize - postsize) / presize. Shrinkage was 100%
if the postchemotherapy CT scan did not show any residual mass.
Various cutoff values and transformations (square root, log) were
assessed.2z
The histology of the resected material was classified as cancer,
mature teratoma, or necrosis according to the worst histologic ele-
ment. Thus, mature teratoma referred to masses that contained ma-
ture teratoma and possibly also necrosis/fibrosis, but no viable cancer
cells, and cancer referred to masses that contained viable cancer
cells and possibly mature teratoma and/or necrosis.
Missing Values
Of the 556 patients who were included in the analysis, 429 had
complete values for all predictors. Missing values were filled in (or
imputed) for 115 patients who were missing one value, and the 12
patients with two or more missing values were excluded. Imputation
was based on the correlation between each variable with missing
values and the other predictors. 23 The correlation was estimated from
the 429 complete cases.
The missing values are filled in (or imputed) assuming their ab-
sence is random. Regression models for the variables with missing
values were estimated from the complete cases. Multiple linear re-
gression models were estimated for the continuous predictors mass
size (on the prechemotherapy or postchemotherapy CT scan) and
prechemotherapy marker values (AFP, HCG, and LDHt,). All contin-
uous predictors had skewed distributions, which became more nor-
mally distributed by log-transformation. Independent variables were
selected in a stepwise manner, with P < .05 for entry of variables
and P < .10 for removal of variables (SPSS/PC+ software; SPSS
Inc, Chicago, IL). A logistic regression model was used to estimate
the presence of teratoma elements in the primary tumor. The correla-
tion matrix between the predictors is shown in Table 2. It appears
that strong correlations exist between several predictors, and thus
imputation based on the values of the other predictors is attractive.
Table 3 shows the independent variables used to impute the missing
values as estimated from the complete cases. Missing values were
imputed in 115 cases. For the patient with missing primary histology,
the predicted probability was .20, and hence the value 0 was imputed
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Table 2. Correlations Between Predictors
Correlation Presize Postsize AFP HCG LDH,, Teratoma
Presize 1.0000
Postsize .5679* 1.0000
AFP .3100* .3155* 1.000
HCG .2179* .1997* .2360* 1.0000
LDH, .5070* .2313* .2047* .2393* 1.0000
Teratoma .1003 .2169* .0445 .13271 -. 0743 1.0000
NOTE. All continuous predictors are log-transformed.
*Two-tailed significance = .001.
tTwo-tailed significance = .01.
(no teratoma). The cases with imputed values were assigned a weight
less than the cases with complete values for all predictors (down-
weighted). This weight is calculated as 1 - p'.s, where py., is the
partial correlation of the predictor with missing values and y, given
the other predictors. The partial correlation was approximated by the
ratio of the Wald statistic and -2 times the log likelihood of a base
model that contains only the intercept in the logistic regression models
predicting necrosis and cancer, respectively.
The results of this analysis were compared with the results ob-
tained when complete cases only were considered.
Statistical Analysis
The histology at resection (necrosis, mature teratoma, or cancer)
was predicted using two statistical models. The first model estimated
the probability of necrosis by comparing patients with necrosis at
resection with patients showing other histologies (teratoma or can-
cer). The second model aimed to distinguish between cancer and
teratoma in the patients who did not have necrosis at resection. This
second analysis estimated the ratio of cancer and teratoma, or the
relative probability of cancer. The use of these two models supports
the clinical notion that the probability of necrosis is of predominant
importance for the decision to resect a residual mass and that the
ratio of cancer and teratoma is a second consideration.3
The probability of necrosis and the relative probability of cancer
were related to factors known before resection (predictors). The odds
ratio (OR) was used as the measure of association. Relationships
between predictors and outcomes were first estimated univariately
within each study. If a test for homogeneity indicated no major
heterogeneity (P > .10) of the relationships, the data were pooled
using the Mantel-Haenszel method (EGRET statistical package; Sta-
tistics and Epidemiology Research Corporation, Seattle, WA). Pre-
dictors have statistically significant effects (P < .05) if the 95%
confidence interval (CI) of the OR does not include the value 1.
Multivariate logistic regression analysis was used to estimate the
probability of necrosis and the relative probability of cancer based
on the combination of predictors. Because the aim of this analysis
is prediction, all variables contributing information should be in-
cluded in the models." Therefore, the multivariate analyses included
all predictors with P less than .50 in the univariate analysis. Of the
three variables related to mass size (prechemotherapy size, postche-
motherapy size, and shrinkage), the postchemotherapy size and
shrinkage were candidates for use in the multivariate models. Differ-
ences between the coefficients of the predictors between the studies
were checked by adding interaction terms of the predictors and study
number. That the relationships were constant in time was checked
by adding interaction terms of the predictors and year of treatment.
Evaluation of Model Performance
Predictive accuracy of the multivariate models can be distin-
guished in reliability (or calibration) and discrimination. Reliability
refers to the amount of agreement between predicted and observed
outcomes. For instance, if patients with certain characteristics are
predicted to have a 70% chance of necrosis at resection, then 70%
of such patients should actually have necrosis at resection. A graphic
impression of reliability was obtained by plotting observed frequen-
cies of the outcome (necrosis/cancer) against predicted probabilities.
Reliability was tested by the Hosmer-Lemeshow goodness-of-fit
test25 (BMDP module LR; BMDP Statistical Software, Inc, Los
Angeles, CA), which evaluates the correspondence between the pre-
dicted probabilities of a model and the observed frequencies over
groups spanning the entire range of probabilities.
Discrimination was assessed using receiver operating characteris-
tic (ROC) analysis. The ROC curve is a plot of the true-positive
rate (sensitivity) versus the false-positive rate (1 - specificity) evalu-
ated at consecutive cutoff points of the predicted probability. The
area under the ROC curve forms a suitable number to summarize
the discriminative ability of a predictive model.26. 27 For all possible
pairs of patients, the area represents the proportion in which the
patients with that outcome (necrosis/cancer) had a higher probability
than the patients without the outcome. A useless predictive model,
such as a coin flip, would yield an area of .5. When the area is 1.0,
the model discriminates perfectly. For our prediction problem, a
value greater than .6 may be interpreted as reasonable, greater than
.7 as satisfactory, and greater than .8 as good with respect to discrimi-
native ability.
Validity of model performance was distinguished internally and
Table 3. Regression Models for Imputation of Missing Values Estimated From the Complete Cases
Dependent Independent r2  N wNec wCan
Presize AFP, LDH,, postsize .50 7 .981 .997
Postsize AFP, LDH,, presize .37 23 .985 .997
AFP HCG, presize, postsize .15 1 .979 -
HCG AFP, LDH,,, teratoma .13 0 .984 -
LDH,, HCG, presize, postsize, teratoma .27 83 .971 .992
Teratoma HCG, LDH,,, postsize - 1 .974 -
Abbreviations: dependent, (log-transformed) dependent variables; independent, independent variables in the regression equations used to impute missing
values; r2, adjusted multiple correlation coefficient indicating the variance explained by the model; N, number of cases where values were imputed; wNec,
weight in logistic regression model predicting necrosis; wCan, weight in logistic regression model distinguishing cancer from teratoma. If shrinkage could
not be calculated because of missing presize, the weight of presize was used.
1179
Copyright © 1995 by the American Society of Clinical Oncology. All rights reserved. 
130.115.129.41. 
Information downloaded from jco.ascopubs.org and provided by Medical Library Erasmus MC on November 13, 2007 from
1180 STEYERBERG ET AL
externally. Internal validity indicates whether the results of the analy- tients had a teratoma-positive primary tumor histology
sis hold for the data under study. Internal validity was assessed with (53%). AFP, HCG, and LDH tumor marker levels were
bootstrapping techniques. 28 Random bootstrap samples were drawn
with replacement from the full sample consisting of all patients (200 elevated before chemotherapy in approximately two
replications). Models were estimated on these bootstrap samples and thirds of all patients (66%, 62%, and 69%, respectively).
evaluated on the full sample. In this way, the discriminative ability Half of the patients had a prechemotherapy mass size --
of the models in future but similar patients is estimated. Moreover, 50 mm (55%), a postchemotherapy mass < 20 mm
bootstrap estimates were used to derive the final predictive models
by correcting the logistic regression coefficients for overoptimism. 29  (52%), or a shrinkage in transversal direction during che-
External validity refers to the validity of the results of this analysis motherapy > 50% (57%). A minority of the patients was
when applied to patients in other centers. To assess external validity, treated before 1981 (11%). The histology at resection was
each study was left out of the full sample once. The models were 45% necrosis, 42% mature teratoma, and 13% cancer.
fit on the remaining studies. Discriminative power was tested on the The relative probability of cancer was 70 / (70 + 236)
study not included in the fitting procedure (test sample).
or 23% on average. Study no. 5 contained patients with
RESULTS larger masses compared with the other studies, with less
Table 4 lists the distribution of patient characteristics shrinkage during chemotherapy, necrosis in 20% only of
in each of the six study groups. Overall, half of the pa- the patients and cancer in 35% of the patients.
Table 4. Patient Characteristics per Study Group
Study No. 1 Study No. 2 Study No. 3 Study No. 4 Study No. 5 Study No. 6 Total
(n = 122) (n = 127) (n = 137) (n = 34) (n - 51) (n = 85) (N = 556)
No. % No. % No. % No. % No. % No. % No. %
Primary tumor histology
Teratoma-positive
Prechemotherapy markers
AFP
Elevated
Median (ng/mL)
HCG
Elevated
Median (IU/L)
LDH
Elevated
Median (U/L)
Prechemotherapy tumor size
0-20 mm
21-50 mm
51-100 mm
> 100 mm
Postchemotherapy tumor size
0-10 mm
11-20 mm
21-50 mm
51-100 mm
> 100 mm
Shrinkage
- 70%
50-69%
30-49%
0-29%
< 0% (increase)
Year of treatment
1975-1980
1981-1985
1986-1993
Histology at resection
Necrosis
Mature teratoma
Cancer
46 38 76 60 84 61 16 47 26 51 45 53 293/555 53
72 59 73 58 97 71 19 59 33 72 65 77 359/548 66
134 44 48 28 - 121 69
67 55 71 56 91 66 22 67 34 74 58 68 343/550 62
2 19 5 15 - 42 11
93 76 86 68 93 68 17 52
357 496 285 542
1 - 32 71 322/465 69
203 399
9 8 21 17 18 13 1 3 - 0 12 13 61/542 11
61 54 61 48 68 50 13 38 - 0 34 40 237/542 44
33 29 34 27 40 29 16 47 10 21 33 39 166/542 31
9 8 11 9 11 8 4 12 37 79 6 7 78/542 14
30 30 54 43 55 40 9 27 - 0 14 17 162/532 31
19 19 31 24 25 18 8 24 - 0 30 36 113/532 21
32 32 26 21 41 30 11 32 - 0 23 27 133/532 25
17 17 12 9 14 10 4 12 8 16 15 18 70/532 13
1 1 4 3 2 2 2 6 43 84 2 2 54/532 10
30 33 49 39 50 37 12 35 - 0 14 17 155/521 30
21 23 35 28 45 33 9 27 - 0 28 33 138/521 27
17 19 15 12 8 6 4 12 3 6 15 18 62/521 12
13 14 23 18 19 14 5 15 35 74 25 30 120/521 23
11 12 5 4 15 11 4 12 9 19 2 2 46/521 9
16 13 7 6 22 16 3 9 11 22 3 4 62/556 11
83 68 67 53 48 35 21 62 34 67 32 38 285/556 51
23 19 53 42 67 49 10 29 6 12 50 59 209/556 38
57 47 66 52 61 45 20 59 10 20 36 42 250/556 45
48 39 51 40 70 51 11 32 23 45 33 39 236/556 42
17 14 10 8 6 4 3 9 18 35 16 19 70/556 13
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Table 5. Relations of Predictors With the Histology at Resection
Necrosis Teratoma Cancer
(n = 250; (n = 236; (n = 70;
45%) 42%) 13%) Necrosis v Other Cancer v Teratoma
No. % No. % No. % OR 95% CI P OR 95% CI P
Primary tumor histology
Teratoma-negative 155 50 78 30 29 11 3.35 2.3-5.0 <.001 -*
Teratoma-positive 94 32 158 54 41 14
Prechemotherapy markers
AFP
Normal 116 61 56 30 17 9 2.74 1.9-4.1 <.001 1.05 .52-2.1 .87
Elevated 130 36 176 49 53 15
HCG
Normal 119 58 67 32 21 10 2.17 1.5-3.2 <.001 1.17 .61-2.3 .60
Elevated 128 37 166 48 49 14
LDH
Elevated 165 51 120 37 37 12 1.69 1.2-2.7 .011 2.62 1.1-6.4 .020
Normal 56 39 78 55 9 6
Prechemotherapy mass size Trend Trend
0-20 mm 35 57 23 38 3 5 1.0 rc .008 1.0 rc .16
21-50 mm 120 51 98 41 19 8 .76 .41-1.4 1.32 .31-6.5
51-100 mm 66 40 74 45 26 16 .51 .29-1.1 2.21 -t
> 100 mm 24 31 36 46 18 23 .34 -t 1.87 -t
Postchemotherapy mass size Trend Trend
0-10 mm 117 72 38 24 7 4 1.0 rc <.001 1.0 rc .46
11-20 mm 62 55 43 38 8 7 .45 .26-.80 1.00 .25-4.0
21-50 mm 42 32 69 52 22 17 .17 .09-.29 1.27 .42-4.0
51-100 mm 11 16 47 67 12 17 .05 .03-.17 0.99 .38-5.1
> 100 mm 10 19 25 46 19 35 .08 -t 2.96 -t
Shrinkage Trend Trend
S70% 114 74 33 21 8 5 1.0 rc <.001 1.0 rc .19
50-69% 72 52 51 37 15 11 .42 .25-.72 1.03 .32-3.4
30-49% 28 45 26 42 8 13 .24 .14-.59 .69 .15-3.0
0-29% 26 22 69 58 25 21 .09 -t .66 -t
< 0% (increase) - 0 38 83 8 17 .01 -t .35 -t
Abbreviation: rc, reference category.
*The ORs were significantly heterogenous between the 6 studies (P = .016).
tThe 95% CI could not be calculated because of empty cells in some studies.
Table 5 lists the results of the univariate analyses. ORs higher prechemotherapy LDH level (Table 5; P = .020).
for necrosis were reasonably homogeneous between stud- The OR of the primary tumor histology was significantly
ies; all tests for homogeneity had P greater than .15. All heterogenous (P = .016). The OR was greater than one
predictors had significant relationships with the finding in studies no. 1 to 4 and less than one in studies no. 5
of necrosis at resection. Patients with a teratoma-negative and 6. Therefore, the primary tumor histology cannot be
primary tumor histology had necrosis at resection in 60% used to distinguish between cancer and teratoma. Preche-
of the cases compared with 32% in patients with teratoma- motherapy AFP and HCG levels were excluded as pre-
positive primary tumor histology. The following preche- dictors in the multivariate models (P > .50). Cancer was
motherapy tumor marker levels were related to the finding found in only 4% (seven of 162) of the patients with
of necrosis at resection: normal AFP, normal HCG, or residual masses < 10 mm and in 5% (eight of 155) of
elevated LDH. Smaller prechemotherapy or postchemo- the patients with a shrinkage >- 70%.
therapy masses contained necrosis more often, as well as The multivariate model for necrosis included 544 pa-
masses that were reduced largely in size during chemo- tients, and 115 of 3,264 (3.5%) of the values were imputed
therapy (large shrinkage). An increase in tumor size dur- (Table 6). All predictors for necrosis were significant (P
ing chemotherapy precluded the finding of necrosis (zero < .003), as well as the multivariate model as a whole (P
of 46 patients). < .0001). Dichotomous characteristics (present/not pres-
Cancer could be distinguished from teratoma by a ent) that predict necrosis included a teratoma-negative
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Table 6. Results of the Logistic Regression Analysis
Necrosis v Other Cancer v Teratoma
(n - 544) (n =299)
OR 95% CI OR 95% Cl
Primary tumor histology
Teratoma-negative v positive 2.46 1.6-3.7
Prechemotherapy marker levels
AFP normal v elevated 2.49 1.6-3.9 -
HCG normal v elevated 2 22 1.4-3.5 -
LDH In(LDH,,)* 2.76 1.8-4.2 1.58 .93-2.7
Postchemotherapy mass size
Sqrt(transversal diameter)' .744 .63-.87 1.17 .99-1.4
Shrinkage
Per 10% decrease* 1.17 1.1-1.3 1.06 .95-1.2
Abbreviation: In(LDH,,), natural logarithm of LHD divided by normal
value; Sqrt, square root.
*Continuous predictors.
primary tumor histology and normal prechemotherapy
AFP and HCG levels. Three other predictors were used
as continuous variables. The natural logarithm (In) ap-
peared to be the optimal transformation of LDHs,. The
square root of the residual mass size was taken. Shrinkage
of the mass during chemotherapy was used as a continu-
ous, untransformed variable, and the OR was calculated
per 10% decrease. Thus, a decrease of 10% indicated
an approximately 1.2-times-higher probability of necrosis
compared with no decrease, simultaneously adjusting for
the other predictors.
The multivariate model for the relative probability of
cancer included 299 patients (77 of 897, or 8.6% of values
imputed). Prechemotherapy LDH level, postchemother-
apy mass size, and shrinkage were used as predictors,
resulting in a significant model (P = .003). The relation-
ship of the predictors did not vary significantly with study
or year of treatment in both multivariate models (P >
.10).
Reliability of the multivariate models is shown in Fig
1. Overall, the correspondence between observed and ex-
pected probabilities is good. In patients with a predicted
probability of necrosis greater than 80%, the observed
probability was 66 of 77 (86%). The goodness-of-fit tests
indicated no lack of fit of the models (necrosis, P = .59;
cancer, P = .34). Discriminative ability of the multivari-
ate models is shown in Fig 2. Clearly, discrimination of
necrosis from another histology is much more feasible
than discrimination of cancer from teratoma.
Validity of the models is listed in Table 7. Assessment
of internal validity indicates that overall discriminative
ability of the model for necrosis is expected to be good
in similar patients (area, .83). The models for cancer will
have less discriminative ability (area, .65).
100
90
80
70
A 60
2 50
40
0
30
20
10
Predicted (%) 0-10 10-20 20-30 30-40 40-50 50-60 60-70 70-80 80-90 90-100
N 82 5 73144 4780 55 70 41 - 48 - 55 - 66 - 46 - 31 -
Fig 1. Reliability of the models predicting necrosis and distin-
guishing cancer from teratoma. Number of patients in each group of
the predicted probability is listed after N.
The external validation procedure mimics the situation
that one of the studies would not have been included
in the analysis. Table 7 shows that the necrosis model
discriminates well in all studies, with some higher dis-
crimination in study no. 4 and some lower discrimination
in study no. 6. The second model discriminates reason-
ably in studies no. 3, 5, and 6.
When the multivariate analysis is restricted to the pa-
0.9
0.9
g
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
False Positive Rate
Fig 2. ROC curves of the models predicting necrosis and distin-
guishing cancer from teratoma, indicating discriminative ability. The
areas under the curves are .839 and .661.
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tients with complete values only, the necrosis model re-
mains very similar with respect to both the ORs and
model performance. However, the model distinguishing
between cancer and teratoma has a smaller OR for LDH
in the complete case analysis (OR = 1.50 v OR = 1.70;
Table 7), and its discriminative ability is inferior to the
model with imputation of missing values (area - .60 v
area ; .65).
Finally, the two multivariate models are presented in
a prognostic score chart (Table 8). This score chart is
intended to facilitate the estimation of the probabilities
of necrosis, mature teratoma, and cancer at resection in
clinical practice using the final models. Scores for each
predictor were derived from the logistic regression coef-
ficients, which were reduced by a correction for overopti-
mism (multiplied by .955 in the necrosis model and by
.870 in the cancer model), and subsequently multiplied
by 10 and rounded to whole numbers. Ten points on the
score chart correspond to an OR of e t = 2.72; an OR of
two (doubling of the odds) is obtained by a score of seven
points. Values for continuous predictors are given with
such intervals that the scores show small steps, but scores
for intermediate values may be estimated by linear inter-
polation.
For individual patients, the scores corresponding to the
values of the predictors can be filled in on the score chart.
An individual sumscore consists of the sum of all scores
and a constant that represents the score if all values were
zero. Figure 3 shows the probabilities corresponding to
this sumscore.
The use of the score chart is illustrated with two pa-
tients (Table 9). Patient no. 1 had a teratoma-negative
primary tumor, normal AFP and HCG levels before che-
motherapy, LDH level three times the normal level, and
a residual mass of 10 mm, which measured 50 mm before
chemotherapy (shrinkage, [50 - 10] / 50; 80%). Patient
Table 7. Internal and External Validation of the Models Predicting
Necrosis and Distinguishing Cancer From Teratoma
Necrosis v Other Cancer v Teratoma
Area Under Area Under
the ROC the ROC
Curve N Curve N
Internal validation
Bootstrapping .83 544 .65 299
External validation
Study no. 1 .83 121 58 65
Study no. 2 .85 127 .55 61
Study no, 3 .84 137 .60 76
Study no. 4 .91 33 .53 14
Study no. 5 .85 42 .67 34
Study no. 6 .75 84 .64 49
no. 2 had a teratoma-positive primary tumor, an elevated
AFP level, and other characteristics the same as patient
no. 1. The sumscores for patient no. 1 are +30 and -12,
and for patient no. 2 + 12 and -12 (necrosis and cancer,
respectively). The corresponding probabilities can be read
from Fig 3. Patient no. 1 has a 95% probability of necro-
sis, leaving approximately 5% for the sum of the probabil-
ities of teratoma and cancer. His relative probability of
cancer is approximately 25% (Fig 3). This means that the
absolute probability of cancer is approximately 25% -5%
(1.25%), and complementarily, the probability of tera-
toma is approximately 3.75%. Alternatively, the exact
probabilities can be calculated using the formulas under
Table 8: necrosis, 94.6%; teratoma, 4.1%; and cancer,
1.3%. The probabilities for patient no. 2 are 75.5%,
18.5%, and 6.0%, respectively.
DISCUSSION
We developed two models to predict the histology of
residual retroperitoneal masses in patients who were
treated with cisplatin-based chemotherapy for metastatic
NSGCT and who obtained normal values of AFP and HCG
levels before resection. The first model aimed to predict
the finding of necrosis only, whereas the second model
was developed to separate cancer from mature teratoma in
patients without necrosis. Individual patient data from six
study groups were available, providing the largest data set
of this type of patients thus far.
3
-5,7-9,13-15,20,21
The model for necrosis consisted of six predictors, that
were highly significant when analyzed alone (univari-
ately) or combined (multivariately). Predictors for necro-
sis were a teratoma-negative primary tumor, normal
prechemotherapy AFP or HCG level, elevated prechemo-
therapy LDH level, a relatively small residual mass, and
a large shrinkage of the mass during chemotherapy. The
model distinguishing cancer from teratoma consisted of
three predictors that together constituted a statistically
significant multivariate model. Cancer was found rela-
tively more often if prechemotherapy LDH level was ele-
vated, the residual mass was larger, and if a large shrink-
age of the mass occurred during chemotherapy.
Higher values of prechemotherapy LDH are thus found
related with a higher probability of necrosis but also with
a higher relative probability of cancer. This implies that
the probability of mature teratoma decreases with higher
prechemotherapy LDH values. The absolute probability
of cancer is lowered by higher LDH values in most pa-
tients because the multivariate OR of LDH for cancer is
smaller than for necrosis (Table 6). In agreement with
previous statements,3 a higher prechemotherapy LDH
level is therefore a fortuitous prognostic sign in patients
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with normal levels of tumor markers AFP and HCG after
chemotherapy. On the other hand, a higher LDH level
has been found to indicate a lower probability of complete
response and a worse survival in patients with metastatic
disease, analyzing from the start of primary chemother-
apy. 10 ,3 0 ,32 It may therefore be postulated that patients with
Table 8. Prognostic Score Chart for the Probability of Necrosis and the
Relative Probability of Cancer at Resection of Residual Masses
in NSGCT Patients With Normal Levels of Tumor Markers AFP
and HCG Before Resection
Necrosis Cancer
Primary tumor histology
Presence of teratoma elements
Prechemotherapy markers
AFP
HCG
LDH,, (LDH/normal value)
Postchemotherapy mass size
Transversal diameter (mm)
Shrinkage (%)
100 presize - postsize/presize
If negative +9
If normal
If normal
0.6
0.8
1.0
1.2
1.5
2.0
3.0
4.5
7.0
2*
5
10
15
20
30
50
70
100
-50
0
50
75
100
Constant
Sumscore (add relevant scores)t
+9
+8
-5
-2
0
+2
+4
+7
+11
+15
+19
-4
-6
-9
-11
-13
-16
20
24
-28
7
0
+7
+11
+15
10
-2
-1
0
+1
+2
+3
+4
+6
+8
+2
+3
+4
+5
+6
+7
+10
+11
+14
3
0
+3
+4
+5
24
*If no mass is detectable on the postchemotherapy CT scan, a size of 2
mm is assumed.
"tThe exact formulas to calculate the sumscores are as follows: sumscore
(necrosis), -9.78 + 8.58 -teratoma-negative + 8.70 AFPnormal +
7.61 HCGnormal + 9.69-ln(LDH,,) - 2.83-Sqrt(postsize) + .147-
shrinkage; sumscore (cancer), -24.18 + 3.95 In (LDH,,) +
1.36 -Sqrt(postsize) + .053 -shrinkage, where the variables teratoma-neg-
ative, AFPnormal, and HCGnormal are I if true, 0 if false, In (LDH,,) is the
natural logarithm of LDH/normal value, postsize is expressed in millimeters,
and shrinkage is expressed as percent. The corresponding probabilities
are calculated with the following formulas: probability (necrosis), 1/[1 +
e .-(..m. .(n.cr.iS)/10)]; probability (cancer), [1 - probability(necrosis)]- [1/
(1 + e- (s. core(cnceri/10)]; probability (teratoma), 1 - [probability(necrosis)
+ probability(cancer)].
c•
ii
0.
100
90
80
70
60
40
30
20
10
Sumscore -40 -35 -30 -25 -20 -15 -10 -5 0 +5 +10 +15+20 +25 +30 +35+40
Probability (%) 2 3 5 9 12 18 27 38 50 62 73 82 88 92 95 97 98
Fig 3. Predicted probabilities corresponding to the sumscores as
calculated with the prognostic score chart (Table 8; see text). For
example, a sumscore of +15 corresponds to a probability of 82%.
residual masses who respond to chemotherapy (as indi-
cated by normalization of AFP/HCG levels) form a favor-
able subgroup of patients with a prechemotherapy high
LDH level.
The two models were reliable in that the observed
probabilities agreed with predicted probabilities. Internal
and external validation procedures showed that necrosis
could be discriminated well from other histologies, but
that cancer could only reasonably be distinguished from
teratoma. It should be realized that the probability of
cancer strongly depends on the probability of necrosis,
as estimated with the first model. For example, if the
estimated probability of necrosis is very high, eg, 95%,
the probability of cancer can never be higher than 5%. If
we use the average relative probability of cancer (23%)
instead of the second model, this results in a risk of cancer
of only 23% * 5% (1.2%). Thus, even when no predictors
for the ratio of cancer and mature teratoma are used, the
risk of cancer will be very low once the probability of
necrosis is high.
The observation that mature teratoma cannot be distin-
guished easily from cancer may be explained partly by
the fact that the histologic distinction between cancer and
mature teratoma is made less clearly than the distinction
between purely benign tissue (necrosis/fibrosis) and other
tissue. For example, one study' 9 described that the histo-
logic classification changed in a substantial proportion of
the patients when reviewed with the Indiana criteria 32
for the diagnosis of cancer. In five patients (12%), the
diagnosis changed from cancer to atypia, and in three
patients (7%), from other diagnoses to cancer.19
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Table 9. Application of the Prognostic Score Chart in Two Hypothetical Patients
Patient Patient
No. 1 No. 2 Necrosis1  Necrosis 2  Cancer, Cancer 2
Primary tumor histology
Presence of teratoma elements Negative Positive + 9  0 -
Prechemotherapy markers
AFP Normal Elevated +9 0
HCG Normal Normal +8 +8 - -
LDH,, (LDH/normal value) 3.0 3.0 +11 +11 +4 +4
Postchemotherapy mass size
Transversal diameter (mm) 10 10 -9 9 +4 +4
Shrinkage (%)
100 (presize - postsize)/presize 80 80 +12 +12 +4 +4
Constant -10 -10 -24 -24
Sumscore (add relevant scores) +30 +12 -12 -12
Probabilities (%)
Using Fig 3 95 -75 -25 -25
Using formulas
Necrosis 94.6 75.5
Teratoma 4.1 18.5
Cancer 1.3 6.0
The final models were presented in a prognostic score
chart, the use of which was illustrated in two patients,
both with residual masses of 10 mm. Taking into account
all prognostic factors, the probability of necrosis was very
high (95%) in the first patient, and somewhat lower (76%)
in the second patient. The probabilities for cancer and
teratoma were 1.3% and 4.1% for the first patient, and
6% and 18% for the second patient, respectively. Should
both patients undergo laparotomy? Or more generally,
can we define thresholds for the decision to resect a resid-
ual mass? Should resection not be performed if the proba-
bility of necrosis is greater than 80%, or is the threshold
as high as 90%? And what should we accept as the risk
of cancer?
These thresholds need to be determined by the balance
between the expected benefits and risks of resection. The
risks of resection include long-term morbidity caused by
surgery, especially ejaculation problems, which depend
on the size and location of the residual mass and the
extent of surgery.6,20 ,33-35 Short-term morbidity consists of
the hospital stay and complications such as hemorrhage,
renal failure, and lymphocele.34 The mortality of laparot-
omy is low, presumably less than 1% in most experienced
centers, but risk estimates for individual patients may be
higher.
If mature teratoma or cancer is present in the residual
mass, the patient is expected to benefit from resection.
The prognosis then is generally favorable, with 5-year
relapse-free survival greater than 85% after resection of
mature teratoma, and 50% to 80% after resection of can-
cer.6-8,16,19,36-38 Resection of viable cancer cells is usually
followed by two additional cycles of chemotherapy. It
has been suggested that this postresection chemotherapy
preferably should be a different regimen than that given
before resection.3' 7 Yet an expectant policy after complete
resection of cancer has also been followed (Horwich A,
personal communication, September 1992).
If resection is not performed, masses that contain ma-
ture teratoma may start to grow during a follow-up of
months or even years (growing teratoma syndrome). 39
Resection may then be more complicated than it would
have been shortly after the end of chemotherapy. Al-
though residual mature teratomas have a less abnormal
karyotype than the primary tumor, a risk of malignant
transformation has been reported.40"" Leaving masses
with residual cancer unresected involves a serious risk.
However, it is uncertain how many of the patients with
histologically viable cancer cells will eventually relapse.
It may be hypothesized that the risk of relapse also de-
pends on the extensiveness of cancer cells in the residual
mass, with a low probability of relapse if only small foci
of malignancy remain. No data are currently available
regarding this relationship. When relapse of malignancy
occurs after leaving mature teratoma or cancer unresected,
salvage chemotherapy is administered. However, these
regimens have rather limited efficacy (approximately
2 5 %1,2,45,46), and late relapses frequently have a high de-
gree of chemotherapy resistance.
Given these uncertainties with the benefits of resection,
it is difficult to indicate thresholds for the probability of
necrosis and cancer. These thresholds also may depend
on country- or center-specific circumstances such as the
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feasibility of frequent follow-up visits with high-quality probabilities are easily calculated with the prognostic
CT scanning of the abdomen.5 If frequent follow-up is score chart and may help to choose the optimal treatment,
impossible, any residual mass should be resected. Finally, taking into account the potential benefits, morbidity, and
in a health-care environment with limited resources, fi- mortality of resection, feasibility of frequent follow-up,
nancial costs of surgery and subsequent hospital stay may the financial costs, and the patient's individual prefer-
provide argument against resection in patients with a high ences.
probability of necrosis or a low probability of cancer.
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